BSE has notified trading members that Aurobindo Pharma Ltd (Scrip Code: 524804/124804) has fixed a record date of April 17, 2026 for its equity share buyback offer. The record date will be used to determine the entitlement and names of equity shareholders eligible to participate in the buyback offer under the Dematerialised Securities – Rolling Settlement Segment.

Key Points

• Aurobindo Pharma Ltd has announced a buyback offer via the tender offer route
• Record date fixed as April 17, 2026 for determining eligible shareholders
• Ex-entitlement date is also April 17, 2026
• Settlement number: DR-612/2026-2027
• Applicable segment: Dematerialised Securities – Rolling Settlement Segment
• Notice issued by BSE’s Listing Compliance and Operations department

Regulatory Changes

No new regulatory changes introduced. This is a standard corporate action notification under existing SEBI buyback regulations.

Compliance Requirements

• Trading members are requested to take note of the record date and communicate relevant information to their clients holding Aurobindo Pharma shares
• Shareholders holding shares as of the record date (April 17, 2026) will be eligible to participate in the buyback offer

Important Dates

• Notice Date: April 13, 2026
• Record Date: April 17, 2026
• Ex-Entitlement Date: April 17, 2026
• Settlement No.: DR-612/2026-2027

Impact Assessment

This circular is relevant to existing shareholders of Aurobindo Pharma Ltd (BSE: 524804). Shareholders holding shares on or before the record date of April 17, 2026 will be eligible to tender their shares in the buyback offer. The buyback provides an exit opportunity for shareholders at the offer price, which may support the stock price around the record date. Trading members should inform their clients of the upcoming record date to enable informed participation decisions.